{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005868","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.825208+00:00","generated_at":"2026-06-17T02:44:51.931580+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Virios reports constructive FDA meeting for IMC-1 fibromyalgia; Long-COVID data expected June 2023","bullets":["End-of-Phase 2 FDA meeting for IMC-1 was constructive; Company seeks guidance to advance to Phase 3.","IMC-1 has been granted FDA Fast Track designation for fibromyalgia.","Topline results from IMC-2 Long-COVID trial (valacyclovir/celecoxib) expected in June 2023.","Company believes existing capital supports general and administrative operations into Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005868","json":"https://secwatch.observer/filing/0001558370-23-005868.json","markdown":"https://secwatch.observer/filing/0001558370-23-005868.md","text":"https://secwatch.observer/filing/0001558370-23-005868.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/0001558370-23-005868-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/tmb-20230413x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:44:51.931580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}